Network Meta-analysis of Chinese patent medicine in treatment of unstable angina pectoris / 中国中药杂志

Network Meta-analysis was used to compare the efficacy and safety of Chinese patent medicines in the treatment of unstable angina pectoris. PubMed, Cochrane Library, CNKI, Wanfang, VIP and other databases were retrieved by computers from the establishment of the databases to June 2020. Randomized controlled trials(RCTs) of Chinese patent medicines for the treatment of unstable angina pectoris were collected. Two investigators independently screened out the literatures, and extracted data according to the inclusion and exclusion criteria. The quality of the included RCTs was evaluated according to the bias risk assessment tool recommended by the Cochrane System Reviewer Manual, and the Stata 13.0 software was used for data analysis and mapping. Through screening, 28 eligible studies were finally included, with the sample size of 2 885 cases, involving 8 Chinese patent medicines. The results of the network Meta-analysis showed that in terms of total effective rate for angina symptom improvement, the order was as follows: Shenshao Capsules > Naoxintong Capsules > Ginkgo Ketone Ester Dripping Pills > Compound Danshen Dripping Pills > Ginkgo Leaf Tablets > Shexiang Baoxin Pills > Tongxinluo Capsules > Yindan Xinnaotong Soft Capsules; in terms of total effective rate for ECG curative effect, the order was as follows: Ginkgo Ketone Ester Dripping Pills>Compound Danshen Dripping Pills > Tongxinluo Capsules > Shenshao Capsules > Shexiang Baoxin Pills > Yindan Xinnaotong Soft Capsules; in terms of hypersensitivity-C-reactive protein curative effect, the order was as follows: Tongxinluo Capsules > Shenshao Capsules > Ginkgo Leaf Tablets>Compound Danshen Dropping Pills> Shexiang Baoxin Pills > Naoxintong Capsules > Yindan Xinnaotong Soft Capsules > Ginkgo Ketone Ester Dropping Pills. Chinese patent medicine combined with conventional therapy can improve the clinical efficacy of unstable angina pectoris. Due to the differences in the quantity and quality of the included studies, the order results of Chinese patent medicines need to be further verified.

Analysis of therapeutic effect of acupuncture at neiguan (PC 6) and zusanli (ST 36) on acute renal colic / 中国针灸

<p><b>OBJECTIVE</b>To observe the efficacy differences among acupuncture at Neiguan (PC 6) and Zusanli (ST 36), dolantin and scopolamine in treatment of acute renal colic, and to verify the clinical effect of acupuncture at Neiguan (PC 6) and Zusanli (ST 36).</p><p><b>METHODS</b>Two hundred and forty patients were randomly divided into an acupuncture group, a scopolamine group and a dolantin group, 80 cases in each group. The acupuncture group was treated by acupuncture at unilateral or bilateral Neiguan (PC 6) and Zusanli (ST 36). The scopolamine group was treated by intramuscular injection of scopolamine combined with intravenous drip of scopolamine, and the dolantin group was treated by intramuscular injection of dolantin. The clinical therapeutic effects were observed 30 min after drug administration or acupuncture, and the onset time of effect and adverse reactions were compared among the groups.</p><p><b>RESULTS</b>The total effective rate of 95.0% (76/80) in the acupuncture group had a similar therapeutic effect to 92.5% (74/80) in dolantin group (P>0.05), which were both superior to 76.3% (61/80) in scopolamine group (both P<0.05). The onset time of (13.24 +/- 2.12) min in the acupuncture group was significant earlier than (23.11 +/- 6.22) min in scopolamine group and (22.17 +/- 3.15) min in dolantin group (both P<0.05), and compared with the other two groups, the adverse reactions in the acupuncture group were significant decreased (both P<0.05).</p><p><b>CONCLUSION</b>Acupuncture at Neiguan (PC 6) and Zusanli (ST 36) has a good analgesic effect with a low incidence of adverse reactions, which is superior to that of dolantin and scopolamine.</p>